A Phase 2 interventional study of Rifampin in Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease and Hypercalcemia, Idiopathic, of Infancy, sponsored by Children's Hospital of Philadelphia. Recruiting at 1 site in United States. Open to participants aged 6 Months to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Children's Hospital of Philadelphia · Phase 2, Interventional, and Treatment
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Idiopathic infantile hypercalcemia (IIH; omim 143880) is a genetic disorder of mineral metabolism characterized by severe hypercalcemia and/or hypercalciuria, suppressed serum levels of parathyroid hormone (PTH) and elevated levels of the active vitamin D metabolite, 1,25(OH)2D. Biallelic inactivating mutations of CYP24A1, the gene encoding the 24-hydroxylase enzyme that represents the principal pathway for inactivation of vitamin D metabolites, cause the most common and severe form of IIH.
Investigators have preliminary data supporting a novel therapeutic approach to repurpose rifampin as an agent to induce over-expression of CYP3A4 and CYP3A5, enzymes that are expressed in the liver and intestine. When these enzymes are induced, the increased enzyme activity provides an alternative catabolic pathway for inactivation of vitamin D metabolites. The purpose of this study is to obtain support for an open label, escalating dose study to assess the effect, safety, and tolerability of once daily oral rifampin in participants with IIH due to inactivating mutations in CYP24A1.
In this study, Investigators will recruit 60 patients with at least one inactivating mutation of CYP24A1. Participants will be observed for 8-weeks before a 16-week treatment phase of rifampin and 8 further weeks of observation. In addition to following the effect of treatment on calcium homeostasis, Investigators will also study the pharmacokinetics of rifampin in this condition and the effect on intestinal calcium absorption.
Exclusion Criteria:
SingleArm: Escalating doses of rifampin (5 and 10 mg/kg/day) (SingleArm)
Drug: Rifampin
Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
Also known as: Rifadin, Rifampicin
Serum albumin-adjusted calcium
Measured at baseline and every 4 weeks
Time frame: up to 32 weeks
Serum parathyroid hormone
Measured at baseline and every 4 weeks
Time frame: up to 32 weeks
Urinary calcium excretion
Measured at baseline and every 4 weeks
Time frame: up to 32 weeks
Intestinal calcium absorption
Measured using stable calcium isotopes five times during the study
Time frame: baseline, 8, 16, 24 and 32 weeks post-dose
Nephrocalcinosis
Renal ultrasound performed before and after treatment
Time frame: Baseline and week 32
Rifampin pharmacokinetics
Measured three times during the study
Time frame: 8, 16 and 24 weeks post-dose
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Philadelphia